Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-08-28, Stock:ABBV, The news for the past five days is as follows:
2018-08-21: NEWS1: SHAREHOLDER ALERT: GLNCY GLCNF COOL FIZZ SBGL GOGO ACAD ABBV: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines.NEWS2: Trade of the Day: AbbVie (ABBV).NEWS3: Trade of the Day: AbbVie (ABBV).NEWS4: 5 Low-Cost Biotech Stocks With High Levels of Growth.NEWS5: SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) and Lead Plaintiff Deadline - September 24, 2018.NEWS6: Trade of the Day: AbbVie (ABBV).
2018-08-22: NEWS1: 3 Undervalued Dividend Stocks to Buy.NEWS2: 3 Undervalued Dividend Stocks to Buy.NEWS3: Health Care Sector Update for 08/22/2018: EXAS,PFE,ARGX,PHG,SNGX.NEWS4: Health Care Sector Update for 08/22/2018: EXAS,PFE,ARGX,PHG,SNGX.NEWS5: Health Care Sector Update for 08/22/2018: ARGX,PHG,SNGX.NEWS6: Health Care Sector Update for 08/22/2018: ARGX,PHG,SNGX.NEWS7: AbbVie Is Focused on Diversifying Its Portfolio in 2018.NEWS8: Oncology Is a Major Growth Driver for AbbVie in 2018.NEWS9: European shares steady as trade talks, U.S. politics fuel uncertainty.NEWS10: AbbVie Has Raised Its EPS Guidance for 2018.NEWS11: Argenx Shares Up After AbbVie Exercises Option To License Immuno-Oncology Drug.NEWS12: AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids.NEWS13: AbbVie Announces Positive Results From Phase 3 Extension Study On Elagolix.NEWS14: AbbVie Announces Positive Results From Phase 3 Extension Study On Elagolix.NEWS15: AbbVie doubles down on cancer project with biotech group Argenx.
2018-08-23: NEWS1: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MD, FPI, FIZZ, ACAD, TTPH and ABBV.NEWS2: AbbVie Posts Positive Data on Elagolix for Uterine Fibroids.NEWS3: AbbVie Posts Positive Data on Elagolix for Uterine Fibroids.NEWS4: AbbVie Posts Positive Data on Elagolix for Uterine Fibroids.NEWS5: Bristol-Myers: FDA To Review SBLA For Empliciti With Pomalidomide, Dexamethasone.NEWS6: Bristol-Myers: FDA To Review SBLA For Empliciti With Pomalidomide, Dexamethasone.
2018-08-24: NEWS1: CLASS ACTION UPDATE for ABBV, TSLA and PDD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders.NEWS2: Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review.NEWS3: Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review.NEWS4: Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review.NEWS5: Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs.NEWS6: Deal of the Week: Ronald McDonald House Houston receives its largest gift ever.
2018-08-27: NEWS1: AbbVie's Imbruvica Approved for Type of Non-Hodgkin Lymphoma.NEWS2: AbbVie's Rare Blood Cancer Drug Combo Snags FDA Approval.NEWS3: We Did The Math FTXH Can Go To $26.NEWS4: We Did The Math FTXH Can Go To $26.NEWS5: Benzinga Pro's 5 Stocks To Watch Today.NEWS6: Today's Research Reports on Trending Tickers: AbbVie and Merck & Co..NEWS7: AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer.NEWS8: AbbVie (ABBV) Up 3.7% Since Last Earnings Report: Can It Continue?.NEWS9: AbbVie (ABBV) Up 3.7% Since Last Earnings Report: Can It Continue?.

Answer: Decrease